
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end? IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.
The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end?
IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.






